Abstract:OBJECTIVE:To investigate the expression of CD19 on childhood acute leukemia (AL) and its significance, and to provide evidence for the diagnosis and differential diagnosis as well as monoclonal antibody-targeting treatment of leukemia.METHODS:There were 210 cases of childhood AL, of which 130 cases were male and 80 were female with a mean age of 9 years old. Using a panel of 27 fluorochrome directly labeled monoclonal antibodies, 210 samples from the patients were analyzed with CD45/SSC double parameters and multi-color flow cytometry to determine the expression of CD19.RESULTS:In the 93 cases of B lineage acute lymphoblastic leukemia (ALL), the positive rate (98.9%, 92/93) of CD19 was significantly higher than that of the other B cell related antigens, such as CD10 (88.2%, 82/93, P = 0.003), CD20 (24.7%, 23/93, P = 0.001) and CD22 (60.2%, 56/93, P = 0.001). CD19 was expressed on all 8 cases of B/myeloid (My) hybrid acute leukemia (HAL) and 1 case of B/T HAL, but was not expressed on all 24 cases of T lineage leukemia and 5 cases of T/My HAL. In the 79 cases of acute myeloid leukemia (AML), only 5 (6.3%) cases expressed CD19. The positive rate (6.3%) of CD19 on AML was significantly lower than that on B lineage ALL (98.9%, P = 0.001). The percentage of CD19 positive cells in B/My HAL (41.6% - 88.7% with a mean of 73.8%) was significant higher than that in CD19(+)-AML (21.4% - 50.4% with a mean of 24.2%; Run Sum test, P = 0.0084). Of the 210 cases, 102 were B lineage related AL including B lineage ALL, B/My HAL and B/T HAL. In B lineage related AL, the sensitivity and the specificity of CD19 was 99.0% (101/102) and 95.4% (13/108) while the positive predictive and the negative predictive values to B lineage were 95.3% (101/106) and 99.0% (103/104), respectively. Using CD19(+) as a single reagent to diagnose B lineage, the false positive rate was 4.6% (5/108) and the false negative rate was 1.0% (1/102) with a general diagnosis index (GDI) of 94.4% [GDI = 1-(false positive rate + false negative rate)].CONCLUSION:CD19 is continuously and stably expressed on all stages of B lineage differentiation. It is a reliable cell membrane marker for diagnosing B lineage ALL and an ideal target for antibody-targeting treatment of leukemia as well; the expression degree of CD19 can be used to distinguish B/My HAL from CD19(+)-AML; CD19 didn't express on normal myeloid cells but did on some AML cells. Therefore it can be used to detect the minimal residual disease.

Research on Immunophenotype of 89 Cases of Chronic Lymphocytic Leukemia

Analysis the immunophenotyping of chronic lymphoid leukemia

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

[Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia].

[The Role of MPO Mrna, IgH Mrna and CD3epsilon Mrna Expressions in Classification of Acute Leukemias].

Expression of CD22 and CD79b from patients with chronic lymphocytic leukemia

Significance of determining immmunophenotype in acute leukemia

Expression of CD19 in 321 Cases of Acute Leukemia

Research Progress on Prognostic Markers of Chronic Lymphocytic Leukemia

[The Expression of CD19 in 210 Cases of Childhood Acute Leukemia and Its Significance].

[Expressions of CD117 and CD11b in Patients with APL at Diagnosis and Post-Treatment].

[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]

Immunophenotyping of 222 Children with Acute Leukemia by Multi-Color Flow Cytometry

Comparison Between CD19 and CD20 Expression Patterns on Acute Leukemic Cells.

Expression of CD11b on peripheral leucocytes in patients with leukemia

Analysis of Relationship Between Immunophenotype and Prognosis of Acute Leukemia

Expression of CD56 in acute leukemia and its clinical significance]

Analysis of CD117 Expression on Leukemia Cells

Immunophenotypic properties association of CLL and ALL patient cells by flow cytometry analysis

Expression and Significance of LAT and CD99 in Precursor T Lymphoblastic Lymphoma

[Characteristics of T-cell Lineage Immunophenotype in 95 Patients with Acute Lymphoid Leukemia].